Discovering breakthroughs in fibrosis and neurodegeneration

Our Pipeline

Blade Therapeutics is advancing a robust pipeline of potential first-in-class, oral, small-molecule therapies for diseases that result from protein deposition (fibrosis) or protein aggregation (neurodegeneration) that disrupt normal cellular, tissue or organ function. This pipeline includes an autotaxin inhibitor and multiple inhibitors of dimeric calpains to treat lung, liver and cardiac fibrosis or neurodegenerative diseases. Since the company’s founding in 2015, Blade has used a combination of in-house drug research and selective in-licensing to build a risk-diversified pipeline.

Our focused approach offers tremendous opportunity to produce disease-modifying, life-saving therapies.

1 Autotaxin Inhibitor
2 Calpain Inhibitor

Scientific Publications